Clinical Trials Logo
  1. Home
  2. Pyoderma Gangrenosum
  3. NCT03311464

A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan

Pyoderma Gangrenosum Clinical Trial

Official title:
A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan

Clinical Trial Summary

This study is designed to investigate the efficacy, safety and pharmacokinetics of adalimumab in subjects in Japan with active ulcer(s) due to Pyoderma Gangrenosum (PG).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03311464
Study type Interventional
Source AbbVie
Contact
Status Completed
Phase Phase 3
Start date October 27, 2017
Completion date April 21, 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06092216 - Spesolimab in Pyoderma Gangrenosum Phase 2
Recruiting NCT04901325 - Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) Phase 2
Completed NCT00791557 - Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease N/A
Terminated NCT02315417 - An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Phase 3
Terminated NCT02318914 - A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum Phase 3
Completed NCT03137160 - An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum Phase 2
Not yet recruiting NCT05984654 - Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum N/A
Completed NCT04895566 - Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma Early Phase 1
Withdrawn NCT04274166 - Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum Phase 2
Completed NCT01882504 - Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum Phase 2
Withdrawn NCT00730717 - Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum Phase 2
Completed NCT03971643 - Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum Phase 2
Not yet recruiting NCT04792957 - JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
Not yet recruiting NCT05821374 - Deucravacitinib in PG Early Phase 1
Terminated NCT03072953 - Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum Phase 2
Recruiting NCT05120726 - A Novel Therapeutic Treatment of Pyoderma Gangrenosum Phase 4
Withdrawn NCT00690846 - Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum Phase 2
Completed NCT01965613 - A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum Phase 2
Recruiting NCT01952275 - Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases N/A
Completed NCT01302795 - Canakinumab for Pyoderma Gangrenosum Phase 2